Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

American College Of Cardiology 2002 Meeting In Brief

This article was originally published in The Gray Sheet

Executive Summary

Was the panel InSync?: "It was unfortunate that there was an impression left with people at the [March 5 circulatory system] panel meeting that somehow something less than all of the data was presented," Medtronic Cardiac Rhythm Management President Steve Mahle said during a March 16 investors call. "There were in fact 71 [additional] patients who met the six-month endpoint prior to the panel meeting. However, the agency "asked us not to submit [that data] because [there] wasn't time [for it] to be submitted to the panel" before the originally scheduled meeting in January. The panel voted 5-4 to recommend approval of the InSync ICD (1"The Gray Sheet" March 11, 2002, p. 3). Data from the 362-patient MIRACLE ICD trial, showing improvement in quality of life, exercise tolerance and functional class, were presented by James Young, MD, The Cleveland Clinic, at the ACC Scientific Sessions annual meeting in Atlanta on March 20...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT016280

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel